

FDA Public Meeting

Postmarketing Requirements for the Class-Wide Extended-Release/Long-Acting Opioid Analgesics

Participant Disclosure Form

May 19-20, 2014

Dear Participant:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the Postmarketing Requirements for the Class-Wide Extended-Release/Long-Acting Opioid Analgesics Public Meeting on May 19-20, 2014 at FDA's White Oak Campus in Silver Spring, MD. This information will be posted publicly along with the transcript, slides and other material from the meeting in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant: _____ Steven P. Stanos, DO _____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions on use of extended-release/long-acting opioid analgesic drug products. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts," sign and return the form.

Janssen- Consulting/Honorarium

Janssen -Cilag Asia Pacific- Consulting/ Honorarium

Endo- Consulting/ Honorarium

Lilly- Consulting / Honorarium

Purdue - Consulting/ Honorarium


Nuvo- Consulting/ Honorarium

Pfizer- Consulting/ Honorarium

MyMatrixx- Consulting/ Honorarium

Mallinckrodt- Consulting/ Honorarium

Zogenix- Consulting/ Honorarium

Signature: _____ 

Please email the form to Janelle Derbis (Janelle.derbis@fda.hhs.gov) by March 31, 2014. If you are asked to make a presentation, you will need to include the same information in your slide presentation.